Novartis India Q1FY26 profit rises 16.6%, revenue up 18.6%
Novartis India reported a 16.6% increase in net profit to ₹322.1 million for Q1FY26, supported by an 18.6% rise in revenue to ₹1,038.1 million. EBITDA margin expanded to 33.6% from 30.02% in the prior year, driven by improved cost management. The Board approved the unaudited results on July 23, 2026, following a review by BSR & Co. LLP, while an impact assessment of new Labour Codes increased employee benefit provisions by ₹7.9 million.
*this image is generated using AI for illustrative purposes only.
Novartis India reported a 16.6% rise in net profit to ₹322.1 million for the quarter ended June 30, 2026, driven by robust operational efficiency and top-line growth. Revenue from operations increased 18.6% to ₹1,038.1 million from ₹875.5 million in the corresponding period of the previous year. The company's EBITDA improved to ₹348.3 million, up from ₹262.8 million, while the EBITDA margin expanded to 33.6% from 30.02% year-on-year, reflecting better cost management and operational leverage.
Financial Performance
Total income for the quarter reached ₹1,125.5 million. The company's profit before tax stood at ₹431.7 million, compared to ₹372.2 million in the same quarter last year. The tax expense for the period was ₹109.6 million. Earnings per share (basic and diluted) for the quarter were reported at ₹13.05.
The following table summarizes the key financial highlights for Q1FY26 on a year-on-year basis:
| Metric | Q1FY26 (₹ in million) | Q1FY25 (₹ in million) |
|---|---|---|
| Revenue from Operations | 1,038.1 | 875.5 |
| Net Profit | 322.1 | 276.2 |
| EBITDA | 348.3 | 262.8 |
| EBITDA Margin | 33.6% | 30.02% |
Operational and Regulatory Updates
Novartis India operates a single segment, Pharmaceutical Business, within India. The Board of Directors approved the unaudited financial results for the quarter ended June 30, 2026, in its meeting held on July 23, 2026. The results were reviewed by the Audit Committee and subjected to a limited review by the statutory auditors, BSR & Co. LLP.
The company noted that the Government of India's notification of four Labour Codes led to an impact assessment, resulting in an increase in the provision for employee benefits by ₹7.9 million for the financial year ended March 31, 2026. This impact was recognized in the employee benefit expense in accordance with Ind AS 19. The company stated it continues to monitor Central and State Rules regarding the Labour Code and will provide appropriate accounting effects based on future developments.
Can Novartis India sustain the current EBITDA margin expansion given the rising employee benefit costs due to new Labour Codes?
What specific operational strategies are driving the robust 18.6% revenue growth, and are they scalable for the remainder of FY26?
How will the implementation of Central and State Rules regarding the Labour Code impact future financial provisions and profitability?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
